Collectively, our data show that NFKB1 activates well-known oncogenic processes in CTCL, supporting the pathological role of aberrantly expressed NFkB factors in this malignancy. The gene discussed is NFKB1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.